blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3777895

EP3777895 - ANTI-BCMA ANTIBODY AND USE THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  15.01.2021
Database last updated on 03.10.2024
FormerThe international publication has been made
Status updated on  03.01.2020
Most recent event   Tooltip25.06.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
ABL Bio Inc.
2F 16 Daewangpangyo-ro 712 beon-gil
Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
[2021/07]
Inventor(s)01 / PARK, Kyungjin
2F, 16, Daewangpangyo-ro 712beon-gil Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
02 / CHUNG, Hyejin
2F, 16, Daewangpangyo-ro 712beon-gil Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
03 / PARK, Kyeongsu
2F, 16, Daewangpangyo-ro 712beon-gil Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
04 / LEE, Yangsoon
2F, 16, Daewangpangyo-ro 712beon-gil Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
05 / CHANG, Mikyung
2F, 16, Daewangpangyo-ro 712beon-gil Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
06 / JEON, Jaehyoung
2F, 16, Daewangpangyo-ro 712beon-gil Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
07 / KIM, Youngkwang
2F, 16, Daewangpangyo-ro 712beon-gil Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
08 / JEONG, Junhyun
2F, 16, Daewangpangyo-ro 712beon-gil Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
09 / YOO, Jiseon
2F, 16, Daewangpangyo-ro 712beon-gil Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
10 / KIM, Yeunju
2F, 16, Daewangpangyo-ro 712beon-gil Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
11 / YEOM, Donghoon
2F, 16, Daewangpangyo-ro 712beon-gil Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
12 / KIM, Eunjung
2F, 16, Daewangpangyo-ro 712beon-gil Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
13 / LEE, Bora
2F, 16, Daewangpangyo-ro 712beon-gil Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
14 / JUNG, Jinwon
2F, 16, Daewangpangyo-ro 712beon-gil Bundang-gu
Seongnam-si, Gyeonggi-do 13488 / KR
 [2021/07]
Representative(s)Swindell & Pearson Limited
48 Friar Gate
Derby DE1 1GY / GB
[2021/07]
Application number, filing date19826406.126.06.2019
[2021/07]
WO2019KR07727
Priority number, dateKR2018007332026.06.2018         Original published format: KR 20180073320
[2021/07]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020004934
Date:02.01.2020
Language:KO
[2020/01]
Type: A1 Application with search report 
No.:EP3777895
Date:17.02.2021
Language:EN
[2021/07]
Search report(s)International search report - published on:KR02.01.2020
(Supplementary) European search report - dispatched on:EP23.11.2021
ClassificationIPC:A61K47/68, C07K16/28, A61K31/40, A61P35/00
[2021/51]
CPC:
C07K16/2878 (EP,KR,US); A61K47/6803 (KR); A61K31/40 (KR);
A61K47/6849 (KR,US); A61K47/6851 (KR); A61P35/00 (EP,US);
A61K2039/505 (US); C07K2317/32 (EP); C07K2317/33 (EP,US);
C07K2317/565 (EP,US); C07K2317/732 (US); C07K2317/76 (EP,US);
C07K2317/92 (EP,US) (-)
Former IPC [2021/07]A61K47/68, C07K16/28, A61K31/40
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/07]
TitleGerman:ANTI-BCMA-ANTIKÖRPER UND VERWENDUNG DAVON[2021/07]
English:ANTI-BCMA ANTIBODY AND USE THEREOF[2021/07]
French:ANTICORPS ANTI-BCMA ET UTILISATION ASSOCIÉE[2021/07]
Entry into regional phase26.10.2020Translation filed 
26.10.2020National basic fee paid 
26.10.2020Search fee paid 
26.10.2020Designation fee(s) paid 
26.10.2020Examination fee paid 
Examination procedure26.10.2020Examination requested  [2021/07]
15.06.2022Amendment by applicant (claims and/or description)
Fees paidRenewal fee
14.06.2021Renewal fee patent year 03
16.06.2022Renewal fee patent year 04
13.06.2023Renewal fee patent year 05
25.06.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]WO2012066058  (BOEHRINGER INGELHEIM INT [DE], et al) [Y] 1-5,7-12 * the whole document *;
 [Y]WO2016090327  (SLOAN KETTERING INST CANCER [US], et al) [Y] 1-5,7-12 * the whole document *;
 [Y]WO2018083204  (ENGMAB SARL [CH]) [Y] 1-5,7-12 * the whole document *;
 [Y]  - ODEN FELIX ET AL, "Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma", MOLECULAR ONCOLOGY, (20150331), vol. 9, no. 7, doi:10.1016/J.MOLONC.2015.03.010, ISSN 1574-7891, pages 1348 - 1358, XP029252531 [Y] 1-5,7-12 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.molonc.2015.03.010
 [Y]  - Dissertation, "Generation of an antibody targeting B cell maturation antigen for the treatment of multiple myeloma and autoimmune diseases", (20140401), URL: http://www.diss.fu-berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000016111/Dissertation_FO_ohne.pdf, (20150615), XP055195743 [Y] 1-5,7-12 * the whole document *
 [Y]  - KEVIN M. FRIEDMAN ET AL, "Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells", HUMAN GENE THERAPY, GB, (20180501), vol. 29, no. 5, doi:10.1089/hum.2018.001, ISSN 1043-0342, pages 585 - 601, XP055626881 [Y] 1-5,7-12 * the whole document *

DOI:   http://dx.doi.org/10.1089/hum.2018.001
International search[A]KR20110126740  (BIOGEN IDEC INC [US]) [A] 1-12 * See abstract; claims 1-31. *;
 [A]US9243058  (ARMITAGE RICHARD J [US], et al) [A] 1-12 * See abstract; paragraph [0059], claims 1-26. *;
 [A]US2016297885  (KUO TRACY CHIA-CHIEN [US], et al) [A] 1-12 * See the entire document. *;
 [A]US2017051068  (PILLARISETTI KODANDARAM [US], et al) [A] 1-12 * See the entire document. *;
 [A]US2018118842  (BRENTJENS RENIER J [US], et al) [A] 1-12 * See the entire document. *;
 [A]  - SANCHEZ, E. et al., "Soluble B- Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma", Clinical Cancer Research, (20160000), vol. 22, no. 13, doi:10.1158/1078-0432.CCR-15-2224, pages 3383 - 3397, XP055474325 [A] 1-12 * See the entire document. *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-15-2224
by applicant   - MOREAUX et al., Eur J Haematol, (20090000), vol. 83, pages 119 - 129
    - "GenBank", Database accession no. NP_035738
    - "GenBank Accession", Database accession no. NM_011608
    - Mol. Cells OT, (20090228), pages 225 - 235
    - Cancer Cell, vol. 19, pages 101 - 113
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.